COMPPARE logo

COMPPARE Advances the Evidence Shaping Prostate Cancer Care

- from an article published on comppare.org Sept. 29, 2026

Nearly 10 years after the launch of the COMPPARE study at the UF Health Proton Therapy Institute, its insights are helping to define the future of prostate cancer treatment. The study’s investigators, led by Principal Investigator Nancy P. Mendenhall, MD, FACR, FASTRO, are sharing new findings and preparing benchmark publications that will impact clinical practice worldwide.

Dr. Mendenhall presented a comprehensive snapshot of proton therapy practice in the United States at the international Particle Therapy Co-Operative Group’s (PTCOG) 64th Annual Conference in June 2026. Among the findings, pencil beam scanning (PBS) centers were found to be more likely to use moderate hypofractionation than centers using double-scattering technology, more frequently treated multiple fields per day and more likely to include pelvic lymph nodes in high-risk patients.

On September 27, 2026, at ASTRO Dr. Mendenhall presented the three-year outcomes of COMPPARE’s randomized arm, which compares standard fractionated and moderately hypofractionated proton therapy. The data helps clinicians better understand whether shorter treatment courses can achieve outcomes comparable to conventional schedule and reduce the treatment burden for patients.

These presentations combined with the publication of an article “Can Engagement Aid in Design and Accrual on Clinical Trials? Observations from COMPPARE” published July 29, 2026, in the International Journal of Radiation Oncology Biology Physics (Red Journal), report the early outcomes of the clinical trial.

Long-term follow-up, presentations and publications continue to be developed from the COMPPARE study, setting benchmarks and moving medicine forward.

For the full article and details about these recent COMPPARE presentations and publications, visit comppare.org.

arrow_back

More News